Alchemab is a biotechnology company that develops antibody therapeutics. The company focuses on advancing novel antibodies with potential applications in various diseases, including Parkinson's disease.

Alex Leech

Ben Larman

Jane Osbourn

Uri Laserson

Rachael Bashford-Rogers

Alchemab

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. 
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Michael J. Fox Foundation

Biomedical Catalyst Fund

DCVC Bio

Dementia Discovery Fund

Lightstone Ventures

RA Capital Management

SV Health Investors

DHVC

DCVC

Alchemab Therapeutics Ltd

Principal Scientist at #Alchemab, Helen Graves, is presenting at the One Nucleus Innovation Seminar in Cambridge on the 'Challenges and Opportunities in Therapeutic Antibody Development'! Don't miss Helen's presentation on 5 September at 16:40pm BST, titled 'Antibodies From Resilient Individuals: A Novel Approach for Antibody Drug Discovery'.
 
Sign up to attend if you haven't already!
 
#biotech #lifesciences #antibodies #neuroscience

#Alchemab is proud to highlight that 15 team members will be taking part in the 3 Peaks Walk in Derbyshire to fundraise for our charity of the year, Age UK!
 
 The team will be heading to Derbyshire to complete 20 miles of hiking across the three highest points in the Peak District National Park on 21st September.
 
We wish them the best of luck on their walk as they continue to fundraise vital funds towards supporting Age UK in Cambridgeshire & Peterborough, who provide various services for older people and their carers.
 
 If you would like to donate to enable #AgeUK to continue their incredible work, please use the link here! https://lnkd.in/gJ4if8Vy

Thank you to everyone who has already donated for this important cause and good luck to the team!
 
#biotech #lifesciences #Cambridgeshire #Peterborough

In case you missed it, #Alchemab was featured in Drug Discovery World’s insightful report: 'Neuroscience: Advances in research and opportunities ahead', highlighting our 'patient-centric approach'! 💡

📰 Download the free report to read more about our unique approach to #drugdiscovery and our program, ATLX-1088, a CD33 inhibitor which 'offers a promising and novel therapeutic approach for the treatment of Alzheimer's disease'.

https://lnkd.in/eCEEdBCu

#biotech #lifesciences #antibodies #neuroscience #alzheimers

Alchemab is supporting The Boston Home as its US charity partner for 2024. Find out more about how Alchemab contributes to this charity's important work to support healthy aging in the article below.  
#healthyaging  #neurology #partnershipsmatter

Alchemab staff are proud to volunteer their time, raising money and awareness for charities aligned with our values and scientific focus. Today we announced that we have selected Age UK Cambridgeshire and Peterborough as our UK Charity for 2024. Read on to learn why we look forward to working with Age UK.

Alchemab Therapeutics Ltd are delighted to share that its paper titled 'A generative foundation model for antibody sequence understanding' has been accepted for two workshops at the 41st [ICML] Int'l Conference on Machine Learning in Vienna, Austria.
 
This paper introduces FAbCon, a generative antibody-specific language model comprising 2.4 billion parameters and will be presented as a poster at the workshops on Machine Learning for Life and Material Science (ML4LMS) on July 26th, and Accessible and Efficient Foundation Models for Biological Discovery (AccML) on July 27th.
 
To read our paper or download our models, use the links in the comments below!

Metric
Company Name	Alchemab	Sarepta Therapeutics, Inc.
Symbol		SRPT
MSH ID	COM:ALCHEMAB	COM:SAREPTA
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	UK	US
Stage		Post-IPO Equity
Employee Count	62	1.31K
Website	alchemab.com	sarepta.com
LinkedIn	alchemab-therapeutics-ltd
Founders

Metric
Market Cap		14.11B
Enterprise Value
Monthly Web Traffic		12.98K
Web Traffic Growth		-0.26
Valuation
Raised Capital		5.96M

Metric
Revenue		1.24B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.09B
EBITDA		-267.82M
Operating Income		-267.82M
Net Income		-535.98M
EPS		-5.80
Diluted EPS		-5.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.88
Operating Profit Margin		0.03
EBITDA Margin		-0.22
Net Profit Margin		0.03
Return on Equity		0.05
Return on Assets		0.01
Return on Capital Employed		0.01

COM:ALCHEMAB

Alchemab

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-16.13
P/B Ratio		14.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		11.03
EV Multiple		207.35

Metric
Days Sales Outstanding		117.02
Days Payables Outstanding		234.37
Days Inventory Outstanding		958.33
Operating Cycle		1.05K
Cash Conversion Cycle		841.56
Asset Turnover		0.44

Metric
Operating Cash Flow		-500.99M
Free Cash Flow		-588.34M
Cash Flow to Debt		-0.32
Operating Cash Flow/Sales		-0.26
Free Cash Flow Yield		-0.05

Metric
Cash & Equivalents		428.43M
Accounts Receivable		-185.70M
Inventory		322.86M
Goodwill
Debt to Capitalization		0.59
Debt to Assets		0.54
Current Ratio		5.44
Quick Ratio		3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.17
R&D to Revenue		0.81
SG&A to Revenue		0.43